Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dean Gaalaas, Karl Odquist

Premium

Dean Gaalaas has joined GeneDx as COO. Gaalaas was previously CEO of Edge Biosystems, but made the move to GeneDx as part of an acquisition by GeneDx's parent company BioReference Laboratories of EdgeBio's sequencing services business, Edge BioServ. Gaalaas joined EdgeBio in 1999, becoming its CEO in 2004.


Pathway Genomics has named Karl Odquist as executive director of managed care. He will be responsible for managed care contracting, reimbursement, government affairs, and clinical evidence generation for the company’s diagnostic services.

Odquist has served in various roles at pharmaceutical and diagnostic companies, most recently at Prometheus Laboratories.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.